| |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each
in combination with tenofovir and
emtricitabine, for management of antiretroviral-naive HIV-1-infected patients:
48 week efficacy and safety
results
of the CASTLE study.
Molina JM, Andrade-Villanueva J, Echevarria J, et al
Lancet. 2008 Aug 23;372(9639):646-55.
Abstract
|
Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in
HIV-1-Infected, Antiretroviral
Naïve
Patients
Treated with Ritonavir-Boosted Atazanavir Plus Fixed-Dose Tenofovir DF/Emtricitabine
Given
Once Daily.
Elion R, Cohen C, Ward D,
HIV Clin Trials. 2008 Jul 1;9(4):213-224.
Abstract
|
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected
patients with
undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, et al
J Antimicrob Chemother. 2007 Nov 13
Abstract
|
| |
A
WEEK-IN-REVIEW FEATURED REPORT
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of
Once-Daily Highly
Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients.
Malan DR, Krantz E, David N, et al
J Acquir Immune Defic Syndr.
2007 Oct 25;
Abstract
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of atazanavir-based highly active antiretroviral
therapy in patients with
virologic suppression switched from a stable, boosted or unboosted
protease inhibitor
treatment
regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, et al
Clin Infect Dis.
2007 Jun 1;44(11):1484-92.
Abstract
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy
in protease
inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL, Chan-Tack KM, Qaqish RB, et al
AIDS Patient Care STDS. 2006 Nov;20(11):745-59
Abstract
|
| |
Influence of atazanavir 200 mg on the intracellular and plasma
pharmacokinetics of saquinavir
and ritonavir 1600/100 mg administered once daily in HIV-infected
patients.
Ford J, Boffito M, Maitland D, et al
J
Antimicrob Chemother.
2006 Sep 19;
Abstract
|
| |
Clinical Outcomes Associated with Concomitant Use of Atazanavir and Proton
Pump Inhibitors
(October).
Sahloff EG, Duggan JM.
Ann Pharmacother. 2006 Sep 12;
Abstract
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
Atazanavir and lopinavir/ritonavir: pharmacokinetics,
safety and efficacy of a promising
double-boosted
protease inhibitor regimen.
Ribera E, Azuaje C, Lopez RM, et al
AIDS. 2006 May 12;20(8):1131-1139.
Abstract
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
A single centre cohort experience with a new once daily antiretroviral
drug.
Stebbing J, Bower M, Holmes P, et al
Postgrad Med J. 2006
May;82(967):343-6.
Abstract
|
| |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in
patients experiencing
multiple
virological failures.
Johnson M, Grinsztejn B, Rodriguez C,
AIDS. 2005 Apr 29;19(7):685-694.
Abstract
|
| |
Long-Term Efficacy and Safety of Atazanavir With Stavudine and
Lamivudine in Patients
Previously
Treated With Nelfinavir or
Atazanavir.
Wood R, Phanuphak P, Cahn P, et al
J Acquir Immune Defic Syndr. 2004
Jun 1;36(2):684-692.
Abstract
|
| |
Therapy with atazanavir plus saquinavir in
patients failing highly active antiretroviral therapy:
a
randomized
comparative pilot trial.
Haas DW, Zala C, Schrader S,
AIDS. 2003 Jun
13;17(9):1339-1349.
Abstract
|
| |
Activities of Atazanavir (BMS-232632) against a Large
Panel of Human Immunodeficiency
Virus
Type 1 Clinical Isolates Resistant to
One or More Approved Protease Inhibitors.
Colonno RJ, Thiry A, Limoli K, Parkin N.
Antimicrob Agents Chemother 2003 Apr;47(4):1324-33
Abstract
|
| |
Results of a Phase 2 Clinical Trial at 48 Weeks
(AI424-007): A Dose-Ranging, Safety,
and
Efficacy Comparative Trial of
Atazanavir at Three Doses in Combination with
Didanosine and
Stavudine in
Antiretroviral-Naive Subjects.
Sanne I, Piliero P, Squires K . et al.
J Infect 2003
Jan;46(1):70-1
Abstract |
|
Atazanavir Journal Citations
Efficacy Studies |
|
ATZ
Journal Main Page
Home
Page